Join
Live feed
·
INSIDERFilingvia Quantisnow
BridgeBio Oncology Therapeutics Inc. logo

Chief Med & Dev Officer Ben Yong was granted 46,670 shares (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
BBOT· BridgeBio Oncology Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BBOT (BridgeBio Oncology Therapeutics Inc.) and more on Quantisnow.